Posted by Michael Wonder on 15 Dec 2020
Almirall announces FDA approval of Klisyri (tirbanibulin), a new innovative topical treatment for actinic keratosis
15 December 2020 - In one of the largest Phase 3 clinical trial programs ever conducted for a topical actinic keratosis treatment, tirbanibulin demonstrated complete clearance of actinic keratosis lesions at day 57 in treated face or scalp areas in a significantly higher number of patients than with vehicle.
Almirall announced today that Klisyri (tirbanibulin) has been approved by the U.S. FDA for the topical treatment of actinic keratosis of the face or scalp.
Klisyri (tirbanibulin) will be launched in the US during the first quarter of 2021.
